Terns Pharmaceuticals (TERN) Stock
Drug company developing liver and immune system treatments. Here's the price, business snapshot, and what's worth knowing about Terns Pharmaceuticals in November 2026.
Terns Pharmaceuticals Inc (TERN) is a clinical‑stage biopharmaceutical company focused on developing small‑molecule therapies for serious diseases, with an emphasis on liver and immune‑related conditions. With a market capitalisation of approximately $710.6m, Terns is primarily valued on its pipeline prospects and upcoming clinical milestones rather than steady revenue. Investors typically watch clinical trial readouts, regulatory interactions and potential partnerships or licensing deals as catalysts. Biotech equities like TERN can be volatile: clinical setbacks, regulatory delays or financing needs can significantly affect the share price. This summary is for general educational purposes only and is not personalised investment advice. Shares may be suitable for investors comfortable with high risk, a long time horizon and the possibility of capital loss; consult a qualified financial adviser before making investment decisions.
Terns Pharmaceuticals (TERN) Stock Forecast
Analyst price target, next 12 months
$53.56
+1.1% vs today's $52.97
Price range over the last 12 months
Close to its 12-month high
Analysts covering Terns Pharmaceuticals have a consensus 12-month target of $53.56, above the current price of $52.97.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Terns Pharmaceuticals stock, anticipating a slight increase in its value.
Financial Health
Terns Pharmaceuticals is showing strong cash flow and book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TERN
Oral Obesity Treatments: Investment Theme Explained
Novo Nordisk has launched the first oral GLP-1 weight loss medication, Wegovy, representing a major evolution in the obesity treatment landscape. This shift from injections to pills creates an investment opportunity in pharmaceutical innovators and the digital health companies enabling broad access.
Published: 6 January 2026
Explore BasketObesity Drug Pricing | Pharma Investment Theme
New agreements with Eli Lilly and Novo Nordisk are set to dramatically lower the cost of popular weight-loss drugs, making them accessible to millions through Medicare. This creates an investment opportunity centered on the major pharmaceutical companies involved and the broader supply chain that will support the expected surge in demand.
Published: 8 November 2025
Explore BasketObesity Drug Stocks: Medicare Coverage Trade-offs
A new agreement between the Trump administration, Eli Lilly, and Novo Nordisk will dramatically lower the cost of GLP-1 weight loss drugs and expand Medicare coverage. This move is expected to significantly increase patient access and boost sales, creating opportunities for the drug manufacturers and their key suppliers.
Published: 7 November 2025
Explore BasketBiotech Buyout Wave Targets Obesity Market 2025
Pfizer's bid for obesity drug maker Metsera has turned into a legal battle after a counteroffer from Novo Nordisk, highlighting the fierce competition in the weight-loss market. This intense M&A activity signals that other biotech companies with promising obesity treatments could become the next valuable acquisition targets.
Published: 1 November 2025
Explore BasketWeight-Loss Drug M&A: Valuation Risk Concerns
Novo Nordisk's superior bid for Metsera has ignited a bidding war with Pfizer, highlighting the intense M&A activity in the obesity drug market. This theme focuses on other biotech companies with promising weight-loss therapies that could become the next acquisition targets.
Published: 31 October 2025
Explore BasketOzempic Price Pressure | Pharma Investment Shift
A recent announcement of plans to slash prices for major weight-loss drugs has created turmoil for market leaders Novo Nordisk and Eli Lilly. This theme explores the investment opportunities that arise for competing pharmaceutical companies and developers of alternative treatments who may benefit from this market disruption.
Published: 21 October 2025
Explore BasketWeight-Loss Drug Shakeup: What's Next for Biotechs?
Following former President Trump's pledge to slash prices for popular weight-loss drugs, uncertainty has hit major pharmaceutical stocks. This theme identifies competitor firms and biotechs that could gain an edge as the pricing landscape for metabolic drugs shifts.
Published: 18 October 2025
Explore BasketObesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: 10 September 2025
Explore BasketCardio-Metabolic Drugs: Beyond Weight Loss Benefits
Following new data showing Novo Nordisk's Wegovy has superior cardiovascular benefits over a key rival, the competitive landscape for weight-loss drugs has intensified. This theme focuses on the pharmaceutical giants battling for dominance and the innovative biotechs whose research in related metabolic and cardiovascular fields is now more valuable than ever.
Published: 1 September 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory interactions can shift investor expectations; these milestones often drive short‑term volatility and longer‑term value.
Scientific Focus
A small‑molecule approach targets liver and immune conditions, which could offer advantages in oral dosing — though clinical proof is required.
Market & Risks
Valuation reflects pipeline potential and a $710m market cap; investors should weigh funding needs, regulatory risk and the speculative nature of biotech.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
